IKENA ONCOLOGY, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.77 USD | -1.12% |
|
+33.08% | -10.15% |
Presenter SpeechUnknown Analyst (Analysts)Thank you for coming to the Ikena fireside chat. My ...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. The Company's lead targeted oncology program, IK-930, is a transcriptional enhanced associate domain 1 (TEAD1) selective Hippo pathway inhibitor, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. The Company's second clinical-stage program targets the RAS signaling pathway with IK-595, a novel MEK-RAF molecular glue. It has IK-175 aryl hydrocarbon receptor (AHR) antagonist program that completed Phase 1 clinical trial. Its partnering portfolio also includes several other immune oncology programs that are available for potential sale or outlicensing, including PY314, a Phase 2 ready TREM2 antagonist, PY159, a Phase 2 ready TREM1 antagonist, and PY265, an IND-ready MARCO antagonist.
Calendar
2024-06-07
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.77
USD
Average target price
3
USD
Spread / Average Target
+69.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.15% | 85.42M | |
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- IKNA Stock
- News Ikena Oncology, Inc.
- Transcript : Ikena Oncology, Inc. Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-14-2022 11
